Wedbush downgraded Chimerix (CMRX) to Neutral from Outperform with a price target of $8.55, up from $7, after the company agreed to be acquired by Jazz Pharmaceuticals (JAZZ) for $8.55 per share in cash, representing a total consideration of approximately $935M.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
- Make smarter investment decisions with TipRanks' Smart Investor Picks, delivered to your inbox every week.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on CMRX:
- Chimerix Merges with Jazz Pharmaceuticals in $935M Deal
- Jazz Pharmaceuticals to acquire Chimerix for $8.55 per share in cash
- Jazz Pharmaceuticals to acquire Chimerix for $8.55 per share in cash, or $935M
- Chimerix’s Strategic Pause and Financial Strength Bolster Long-term Buy Rating Amid Regulatory Milestones
- CMRX Earnings this Week: How Will it Perform?